Canadian Health&Care Mall: The Ballooning Posterior Leaflet Syndrome

cardiac arrhythmiasThe validity scales revealed no abnormalities. Seven of the eight symptom-free patients had entirely normal MMPIs. The eighth, discovered because she was the niece of a woman who died from the ballooning posterior leaflet syndrome, showed an abnormal test score for hypomania. Of the six symptomatic patients with the full ballooning posterior leaflet syndrome (Table 1), five had abnormal scores for hysteria and hypochondriasis, four showed abnormal scores for depression, psychopathic deviate and schizophrenia, three had abnormal scores for psychasthenia, two had abnormal scores for social inversion, and one showed abnormal scores for paranoia, hypomania and masculinity-femininity. All these symthoms can be abserved at patients suffering from “persecution syndrome”. Canadian Health&Care Mall has all the necessary medicaments and qualified stuff to held you deal with the treatment of such disorders – Two of these six patients have been resuscitated from a near-fatal arrhythmia (patients 2 and 6), and two have demonstrated frequent PVCs during electrocardiographic monitoring procedures (patients 4 and 5). The two patients with life-threatening arrhythmias (ventricular fibrillation and ventricular tachycardia) were abnormal in at least four categories of the MMPI, while the other patients showed abnormal elevations on at least three of the scales.

Of the four patients with valvular aortic stenosis, all presented with angina pectoris, two with exertional shortness of breath, and one with occasional dizziness. All four exhibited normal MMPIs with normal validity scales (Table 2). Continue reading “Canadian Health&Care Mall: The Ballooning Posterior Leaflet Syndrome”

Canadian Health&Care Mall: Congenital Heart Disease in a Tetra-X Woman

congenital heart diseaseTetra-X is a rare abnormality of the sex chromosomes; only 20 cases have been reported previously. It is thought to result from nondisjunctions during the first and second meiotic divisions of oogenesis. The clinical features are nonspecific and have included mental retardation reduction of dermal ridges, behavioral disturbances, hypertelorism with epicanthal folds, eye anomalies (myopia, squints, nystagmus, iridoschisis), skeletal abnormalities (clinodactyly, radioulnar synostosis, dislocation of the hip, tall stature), menstrual irregularities with reduced fertility, and congenital heart disease.

The patient to be presented is the first case of tetra-X to be studied at autopsy and the first with documented congenital heart disease. Read more about congenital heart disease on Canadian Health&care Mall – Continue reading “Canadian Health&Care Mall: Congenital Heart Disease in a Tetra-X Woman”

Canadian Health&Care Mall: Effects of Cigarette Reduction on Cardiovascular Risk Factors and Subjective Measures

cardiovascular risk factorsAlthough smoking cessation has been clearly demonstrated to reduce subsequent cardiovascular mor-tality, whether smoking reduction or “reduced exposure” products confer any health benefits is still unknown. Due to the difficulty in carrying out prospective, randomized studies assessing long-term outcomes data, use of other measures (ie, biomarkers) that are known to be altered during smoking and normalize during smoking cessation is an attractive alternative in researching risk reduction approaches. Partial normalization of reliable biomarkers during smoking reduction may indicate that this approach confers some health benefits especially if changes in the selected biomarkers are the underlying cause for smoking-related disease. To date, few studies have systematically examined the reliability and dose-responsiveness of biomarkers for CVD.

This study demonstrated that certain biomarkers of CVD risk factors (eg, hemoglobin, hematocrit, RBC count, WBC count, lipoproteins concentrations, heart rate, respiratory symptoms) known to be affected by smoking are relatively stable over time when amount smoking is maintained at a constant rate but are altered in response to changes in smoking behavior. This suggests that some of these measures are likely to be sensitive to changes in tobacco toxin exposure. The results seen in this study are consistent with two previous studies that assessed the effect of smoking reduction on various biomarkers. An open-label study in which subjects were encouraged to reduce smoking by at least 50% for 8 weeks and then quit smoking entirely for 8 weeks while using ad libitum nicotine nasal spray found significant decreases in WBC blood count, RBC count, hemoglobin, hematocrit, and fibrinogen with significantly increased HDL/low-density lipoprotein (LDL) ratio after both reduction and cessation. For WBC and RBC counts, greater improvements were observed after cessation than after reduction. Changes to LDL and HDL (decrease and increase, respectively) were statistically significant only after cessation, although nonsignificant changes were seen with reduction as well. A study of 25 subjects able to reduce smoking by > 50% found that these subjects had significantly higher HDL levels and significantly lower total cholesterol/HDL ratio, LDL, hemoglobin, hematocrit, FEV1, and systolic BP than observed prior to reduction. Canadian Health&Care Mall – is full of various drugs including Antihistamine Preparations.

Continue reading “Canadian Health&Care Mall: Effects of Cigarette Reduction on Cardiovascular Risk Factors and Subjective Measures”

Results of Effects of Cigarette Reduction on Cardiovascular Risk Factors and Subjective Measures

SmokedRecruitment and Characteristics of Subjects

A total of 151 subjects were enrolled in this study, Of these, 102 subjects were randomized to the experimental group and 49 subjects were randomized to the wait list control (Fig 1). Among those in the wait list control, 3 patients dropped out during the wait list portion of the study and 13 patients dropped out during the reduction phase of the study. Of the participants randomized to the experimental group, no subjects dropped out prior to or during baseline measurements; a total of 25 subjects dropped out by week 6, 34 subjects by week 8, and 37 subjects by week 12 of treatment. In total, 98 of 151 subjects completed treatment through week 12, and 53 subjects dropped out. Table 2 describes the characteristics of all randomized subjects, subjects who reduced by at least 40% at week 4, from weeks 4 to 6, and from weeks 4 to 12. Logistic regression was used to compare the groups on differences in demographics and smoking history. The only significant differences among these groups were for age between all randomized subjects compared to those subjects who constituted the sample for visit 4 (p = 0.0031), visit 6 (p = 0.001), and visit 12 (p = 0.02); for years smoked between all randomized subjects and subjects who comprised the sample for visit 4 (p = 0.04) and visit 6 (p = 0.01); and for motivation to quit between all randomized subjects, compared to subjects who comprised the sample for visit 12 (p = 0.03) and between subjects who comprised the sample for visit 4 compared to visit 12 (p = 0.05). The results show that subjects who were older (odds ratio, 1.04, p = 0.02) and reported more motivation to quit (odds ratio, 1.13; p = 0.04) were more successful in sustaining reduction through week 12.

Continue reading “Results of Effects of Cigarette Reduction on Cardiovascular Risk Factors and Subjective Measures”

Canadian Health&Care Mall: Research about Effects of Cigarette Reduction on Cardiovascular Risk Factors and Subjective Measures

Cigarettes per dayStudy Design

Details of the study design have been described previously. In brief, cigarette smokers from 18 to 70 years of age and interested in significantly reducing cigarette use were recruited. Inclusion criteria included the following: (1) smoking from 15 to 45 cigarettes per day (CPD) for the past year (in order to reduce heterogeneity); (2) uninterested in and no plans for quitting in the next 30 days; (3) good physical health (no unstable medical condition); (4) no contraindications for nicotine replacement use; (5) good mental health (eg, not meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,11 criteria for any psychiatric diagnosis, including substance abuse, within the past 6 months); (6) not using other tobacco or nicotine products or medications that might affect tobacco use or be affected by reduction of tobacco use; and (7) for female subjects, not pregnant or nursing. The University of Minnesota Institutional Review Board approved this study and the informed consent procedures. Improve your mental state with Wellbutrin sold by Canadian Health&Care Mall –

Subjects who met inclusion criteria monitored their use of cigarettes (and other tobacco products) on a daily basis for a period of 2 weeks to assess baseline tobacco use. The following week, subjects returned for the baseline visit (visit – 1), when they were randomly assigned to the experimental cigarette reduction group or to the wait list control group for 6 weeks. Subjects monitored their smoking for another week, after which baseline measures were repeated at a second baseline visit (visit 0). Subjects assigned to the wait list control were the basis for the analysis that examined the consistency or intrasubject reliability across the various biomarkers for health risks or tobacco toxin exposure. This group was required to maintain and monitor smoking for a total period of 8 weeks. Subjects were assessed on all dependent measures during the first two baseline visits and then at weeks 4 and 6 after the second baseline visit. After the 8 weeks of ad libitum smoking, subjects entered the treatment reduction phase as described below.

Continue reading “Canadian Health&Care Mall: Research about Effects of Cigarette Reduction on Cardiovascular Risk Factors and Subjective Measures”

Effects of Cigarette Reduction on Cardiovascular Risk Factors and Subjective Measures

Cardiovascular diseaseAlthough the idea of reducing tobacco toxin exposure among continuing smokers is not a new concept, recent efforts by the tobacco industry to develop and market potential reduced-exposure products have resulted in an increased interest in examining this approach. The escalating introduction of potential reduced-exposure products has prompted the US Food and Drug Administration to sponsor a report from the Institute of Medicine and for the National Cancer Institute to convene an expert panel to consider the feasibility of this approach, the necessary science and systems that need to be in place in order to ensure public health, and the specific research areas that will need to be pursued. The identification of reliable and valid biomarkers for tobacco toxin exposure was determined to be a particularly important area of research.

Biomarkers can be considered as measures of the following: (1) toxins specifically related to exposure of tobacco constituents, such as nicotine or tobacco-specific nitrosamines; (2) risk contributors to disease, such as lipoproteins, C-reactive protein, WBC count; (3) disease markers such as pulmonary function; or (4) clinical outcome measures, such as hospitalizations, occurrence of disease, or death. Smokers compared to nonsmokers have significantly elevated risk factors for cardiovascular disease (CVD), and these risk factors improve among smokers after cessation of cigarettes. To date, few studies have examined the effects of changes in cigarette dose on cardiovascular risk factors. Of the studies that currently exist, the results show significant improvement on these measures; however, the sample sizes have tended to be small, and no control groups have been used.

Continue reading “Effects of Cigarette Reduction on Cardiovascular Risk Factors and Subjective Measures”

Disscusion of Myocardial Dysfunction and Hemolytic Anemia in a Patient with Mycoplasma pneumoniae Infection

Myocardial involvementMyocardial involvement associated with infection with Mycoplasma pneumoniae was first reported by Rosner and associates, who described an 18-year-old patient who developed complete atrioventricular block during an upper-respiratory-tract illness. This patient had a change in the complement-fixation test consistent with recent infection with Mycoplasma, but levels of cold agglutinins and serum cardiac enzymes were normal. In a series of 18 patients with asymptomatic myocarditis associated with viral-like illnesses reported by Lewis et al, two patients had serologically proven infection with Mycoplasma. The myocarditis in these two patients was manifested only by abnormalities of the ST-T wave on the ECG and occurred concurrently with respiratory symptoms.

The cold-agglutinin hemolytic anemia associated with infections with Mycoplasma pneumoniae characteristically occurs in the second and third weeks of the illness, with the appearance of cold agglutinins in significant titers (> 1:512). The cold agglutinins are IgM antibodies with anti-I erythrocyte antigen specificity and have a high thermal maximum in those patients who develop hemolytic anemia. El Khatib and Lemer recently reported serologically proven infection with Mycoplasma in a patient with asymptomatic myoperi-carditis and hemolytic anemia associated with a markedly elevated titer of cold agglutinins. Of significant note is the fact that the myocarditis and hemolytic anemia occurred simultaneously on the 22nd day of illness, after resolution of an acute pneumonitis. At no time was the patients anemia severe enough to warrant transfusion. Continue reading “Disscusion of Myocardial Dysfunction and Hemolytic Anemia in a Patient with Mycoplasma pneumoniae Infection”

Myocardial Dysfunction and Hemolytic Anemia in a Patient with Mycoplasma pneumoniae Infection

Mycoplasma pneumoniaeMycoplasma pneumoniae is a common respiratory pathogen that may be associated with a variety of other complications, including erythema multiforme, meningitis, peripheral neuropathy, and hemolytic anemia. Myocarditis has also been previously described in association with infection with this organism, but the manifestations have been minor, both in the electrocardiographic change (nonspecific abnormalities of the ST-T wave) and in signs of cardiac dysfunction. In this communication, we present a patient who developed signs and symptoms of myocarditis during the course of infection withMycoplasma pneumoniae associated with severe hemolytic anemia.

Case Report

A 49-year-old white woman was hospitalized for evaluation of increasing shortness of breath, a cough productive of moderate amounts of yellowish-brown sputum, and fever of four days’ duration. There was no prior history of cardiac disease. Continue reading “Myocardial Dysfunction and Hemolytic Anemia in a Patient with Mycoplasma pneumoniae Infection”

Blog at

Up ↑